within Pharmacolibrary.Drugs.ATC.N;

model N07AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0001,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07AB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bethanechol is a synthetic choline ester and a parasympathomimetic agent that selectively stimulates muscarinic receptors without effect on nicotinic receptors. It is primarily used to treat urinary retention by stimulating contraction of the bladder muscle and for certain gastrointestinal disorders like postoperative ileus. It is an older drug and still approved in several countries for specific indications.</p><h4>Pharmacokinetics</h4><p>No well-characterized clinical pharmacokinetic studies available in humans; PK parameters are estimated based on limited animal data and drug class behavior.</p><h4>References</h4><ol><li><p>Jeong, HM, et al., &amp; Lee, BJ (2025). Release-modulating mechanism and comparative pharmacokinetics in beagle dogs of bethanechol-loaded oral dosage forms. <i>International journal of pharmaceutics</i> 669 125091–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2024.125091&quot;>10.1016/j.ijpharm.2024.125091</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39701474/&quot;>https://pubmed.ncbi.nlm.nih.gov/39701474</a></p></li><li><p>Takanashi, M, et al., &amp; Kobayashi, K (2023). Predictive factors for the success of trial catheter removal for women with urinary retention. <i>Lower urinary tract symptoms</i> 15(1) 4–10. DOI:<a href=&quot;https://doi.org/10.1111/luts.12464&quot;>10.1111/luts.12464</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36252953/&quot;>https://pubmed.ncbi.nlm.nih.gov/36252953</a></p></li><li><p>Kirby, MG, et al., &amp; Powell, JR (1989). Effect of metoclopramide, bethanechol, and loperamide on gastric residence time, gastric emptying, and mouth-to-cecum transit time. <i>Pharmacotherapy</i> 9(4) 226–231. DOI:<a href=&quot;https://doi.org/10.1002/j.1875-9114.1989.tb04130.x&quot;>10.1002/j.1875-9114.1989.tb04130.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2771808/&quot;>https://pubmed.ncbi.nlm.nih.gov/2771808</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07AB02;
